The science
Semaglutide research: one mechanism, many endpoints, large and consistent effects.
Mechanism of action, the pivotal phase-3 trials, and the head-to-head comparisons — organized by finding, heavily cited.
The short version
Semaglutide research is unusually deep for a single drug. It works by switching on one receptor — the GLP-1 receptor — but that one switch reaches the pancreas, the stomach, the kidneys, the heart, and, importantly, the brain. In studies, turning that switch on lowers blood sugar, slows digestion, and quiets appetite by acting on hunger centers in the brain. The result, across very large trials, is weight loss, better blood sugar, fewer heart attacks and strokes in higher-risk people, and slower kidney decline in diabetes.
The research below is grouped by what was actually measured. The mechanism comes first, then the major human trials with their real numbers, then two comparisons people search for most: semaglutide versus tirzepatide, and the weight-loss data specifically. Animal studies fill in how the brain part works. Everything quantitative points to a numbered source on the references page.
What is semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analogue of the natural incretin hormone GLP-1, which the gut releases after a meal [15]. It is a 31-amino-acid peptide sharing roughly 94% sequence homology with native GLP-1, with a molecular weight near 4,114 Da and the formula C187H291N45O59. Two engineered features give it durability: an alpha-aminoisobutyric-acid (Aib) substitution at position 8 that resists the DPP-4 enzyme, and a C18 fatty-di-acid side chain that binds albumin and slows clearance [15]. It is approved across type 2 diabetes, chronic weight management, cardiovascular risk reduction, and (2025) metabolic dysfunction-associated steatohepatitis.
Semaglutide peptide structure and class
As a semaglutide peptide, the molecule sits in the incretin-mimetic class: drugs that imitate gut hormones to amplify glucose-dependent insulin release. Native GLP-1 is destroyed in about two minutes by DPP-4; the Aib-8 substitution blocks that cleavage, and reversible albumin binding via the lipid side chain protects the peptide from renal filtration [15]. The net effect is a circulating half-life of roughly one week rather than minutes [13][15]. This is the structural basis for once-weekly dosing and the central fact of the molecule's pharmacology.
How does semaglutide work
To answer how does semaglutide work: it activates GLP-1 receptors, which sets off several glucose-dependent effects. Through the Gs/adenylate-cyclase/cAMP/PKA pathway it potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, and slows gastric emptying [5][15]. Its weight-lowering effect is primarily central: rodent work shows semaglutide directly accesses the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus, where it activates satiety-promoting POMC/CART neurons and inhibits hunger-driving NPY/AgRP neurons, reducing food intake and altering food preference without lowering energy expenditure [4]. The reward-pathway component is the basis for research into appetite and alcohol behavior.
Semaglutide weight loss: the STEP program
The headline weight result comes from STEP 1: in 1,961 adults with overweight or obesity and without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo — a difference of about 12.4 percentage points [1]. The STEP 1 primary findings were also reported in the broader program literature describing 2.4 mg once weekly for weight management in adults with overweight or obesity, including those with type 2 diabetes (STEP 2) [10].
A caveat the program itself surfaced: a DXA body-composition substudy found that the weight lost comprised both fat and a meaningful proportion of lean mass, motivating research into protein intake and resistance training to preserve muscle [9]. This is the semaglutide weight loss picture in full — large mean loss, with a composition caveat worth knowing.
Cardiovascular and kidney outcomes
The outcomes trials are the strongest part of the record. SUSTAIN-6 (n=3,297, type 2 diabetes at cardiovascular risk) reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.74; 95% CI 0.58-0.95), while diabetic-retinopathy complications were higher (HR 1.76; 95% CI 1.11-2.78) [2]. SELECT (n=17,604, established cardiovascular disease and overweight/obesity without diabetes) cut the same composite by 20% (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. FLOW (n=3,533, type 2 diabetes with chronic kidney disease) reduced major kidney-disease events — kidney failure, a 50% or greater eGFR decline, or kidney/cardiovascular death — by 24% (HR 0.76; 95% CI 0.66-0.88) [6].
Semaglutide vs tirzepatide
On semaglutide vs tirzepatide, the only direct head-to-head obesity trial is SURMOUNT-5. In 751 adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%, an advantage of about 6.5 percentage points that was statistically significant (P<0.001) [7]. Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a GLP-1-only agonist. The comparison is one of degree within overlapping mechanisms — both are large effects, with tirzepatide larger in this trial.
Against another GLP-1 agonist, dulaglutide, semaglutide produced greater reductions in HbA1c and body weight in SUSTAIN 7 [12]. And against oral medications generally, a clinical PK study found semaglutide had no clinically relevant effect on the pharmacokinetics of co-administered metformin, warfarin, atorvastatin, or digoxin, consistent with low drug-interaction risk despite delayed gastric emptying [8].
Oral semaglutide and recent pharmacokinetics work
A meta-analysis of once-daily oral semaglutide reported efficacy in glycemic control and weight, with cardiovascular outcomes consistent with the GLP-1 receptor-agonist class in type 2 diabetes [11]. A 2024 systematic review of semaglutide pharmacokinetics confirmed the long elimination half-life supporting once-weekly subcutaneous administration and summarized AUC, Cmax, time-to-Cmax, and clearance across formulations [13]. The StatPearls reference consolidates the practical pharmacology: a half-life of about one week (roughly five weeks to clearance), 94% GLP-1 homology, and an oral bioavailability of only about 0.4-1% with the SNAC absorption enhancer [15]. The detail on the tablet is on the oral semaglutide page.